New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
04:55 EDTTLOG, TLOG, TLOG, TLOG, TLOG, AG, AG, AG, AG, AG, FMI, FMI, FMI, FMI, FMI, NLNK, NLNK, NLNK, NLNK, NLNK, TSRO, TSRO, TSRO, TSRO, TSRO, FPRX, FPRX, FPRX, FPRX, FPRX, SNSS, SNSS, SNSS, SNSS, SNSS, TROV, TROV, TROV, TROV, TROV, AZN, AZN, AZN, AZN, AZN, MRK, MRK, MRK, MRK, MRK, PFE, PFE, PFE, PFE, PFE, NVS, NVS, NVS, NVS, NVS, PPHM, PPHM, PPHM, PPHM, PPHMAmerican Association of Cancer Research to hold annual meeting
2014 Annual Meeting 2014 is being held in San Diego, California on April 5-9.
News For TLOG;NVS;PFE;MRK;AZN;TROV;SNSS;FPRX;TSRO;NLNK;FMI;AG;PPHM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
October 14, 2014
11:23 EDTAZN, NVS, MRK, PFEBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
11:19 EDTNLNKNIH says several potential Ebola treatments under development
Subscribe for More Information
10:10 EDTNLNKNIH director says supporting BioCryst, Chimerix Ebola treatments
Subscribe for More Information
09:04 EDTNLNKChinese company says drug can cure Ebola, Reuters reports
Subscribe for More Information
07:08 EDTAGFirst Majestic reports Q3 silver production in Mexico up 5% YoY
First Majestic Silver announced that total production at its five operating silver mines in Mexico for the Q3 ending September 30 reached 3,523,536 equivalent ounces of silver, representing a 5% increase compared to the same quarter in 2013. Total silver production for the quarter consisted of 2,680,439 ounces of silver, relatively unchanged compared to the same quarter in 2013. In addition, 9,703,792 pounds of lead and 3,222,877 pounds of zinc were produced, representing an increase of 14% and 44%, respectively, compared to the same quarter of the previous year. Also produced were 2,781 ounces of gold, representing a 5% decrease compared to the Q3 of 2013.
October 13, 2014
11:15 EDTNLNKEbola vaccine licensed to NewLink begins human trials
Canada's Minister of Health announced the launch of Phase 1 clinical trials for Canada's Ebola vaccine, which was developed by scientists at the Public Health Agency of Canada's National Microbiology Laboratory. The Canadian government owns the intellectual property associated with this vaccine and has licensed the rights to NewLink Genetics through its wholly owned subsidiary BioProtection Systems. The Phase 1 clinical trial will test the vaccine on a small group of people to assess its safety, determine the appropriate dosage and identify any side effects.
10:08 EDTAZNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:21 EDTAZNOn The Fly: Pre-market Movers
Subscribe for More Information
08:01 EDTPFEPfizer announces FDA acceptance of Palbociclib NDA with priority review
Subscribe for More Information
07:53 EDTAZNAstraZeneca upgraded to Buy from Hold at Jefferies
Subscribe for More Information
07:37 EDTMRKAmerican Society of Anesthesiologists to hold annual meeting
Subscribe for More Information
05:27 EDTAZNAstraZeneca upgraded to Buy from Hold at Jefferies
Subscribe for More Information
October 12, 2014
19:26 EDTNLNKPatient being evaluated at Boston hospital for possible Ebola, Boston Globe says
Health officials say that a man that recently traveled to Liberia is being assessed at Beth Israel Deaconess hospital in Boston for the Ebola virus, the Boston Globe says. Drug companies that are working on experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
19:12 EDTNLNKCDC confirms Texas healthcare worker positive for Ebola
Subscribe for More Information
14:18 EDTNLNKNY's JFK Airport begins Ebola screenings, WSJ says
Subscribe for More Information
12:48 EDTNLNKTexas health-care worker tests positive for Ebola, WSJ says
Subscribe for More Information
October 10, 2014
10:54 EDTNLNKMapp looking to up production of experimental Ebola treatment, WSJ says
Mapp Biopharmaceutical is aiming to broaden the manufacturing of its experimental Ebola treatment, ZMapp, according to The Wall Street Journal, citing comments from the company. Mapp said that the treatment was given to a few infected individuals prior to supplies running out two months ago. Drug companies that are working on experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
08:06 EDTPFEPfizer presents Staphylococcus aureus vaccine Phase 1, Phase 2 study data
Subscribe for More Information
05:47 EDTSNSSStocks with implied volatility movement; SNSS GPOR
Subscribe for More Information
05:13 EDTNVSNovartis reports new analyses of AIN457 Phase III data show consistent efficacy
Novartis announced that new analyses of AIN457 Phase III studies showed that treatment with secukinumab 300 mg resulted in higher rates of clear to almost clear skin at Week 12 versus placebo, regardless of patients' psoriasis disease severity. Secukinumab's new mode of action stops interleukin-17A, which plays a central role in the development of psoriasis. In the analyses, the majority of patients across two disease severity subgroups, including those with severe psoriasis, experienced complete clear to almost clear skin measured as 100 or 90% reduction of respective baseline PASI, or Psoriasis Area and Severity Index. Skin clearance was sustained through one year of treatment. This is important as historically, psoriasis patients' disease severity at the start of treatment has been shown to negatively impact their response to other therapies. Disease severity subgroups were PASI less than or equal to 20 and PASI greater than 20. PASI measures redness, scaling and thickness of psoriatic plaques and the impact in regions of the body. These findings reconfirm the significantly better responses seen in the published FIXTURE study, where secukinumab showed superiority to Enbrel, a standard of care anti-TNF medication.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use